Skip to content
Screener

Prime Medicine PRME Total Operating Expenses

Total Operating Expenses at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$131.71M-11.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$138.95M+9.6%
Sana Biotechnology logo
Sana BiotechnologySANA
$48.61M-4.0%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$41.11M-5.5%
Wave Life Sciences logo
Wave Life SciencesWVE
$76.07M+23.8%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$15.62M-8.1%

Segments

By segment

See full
Reportable Segment$44.44M-18.4%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$43.3M+18.9%
Net income-$42.1M+19.9%
EPS (diluted)-$0.24+41.5%

Balance sheet

See full
Cash & equivalents$61.1M-9.4%
Total debt$112.5M-6.1%
Total equity$39.8M-34.6%
Total assets$249.0M-10.7%

Cash flow

See full
Operating cash flow-$41.0M+0.9%
CapEx$46.0K-97.1%
Free cash flow-$41.1M+4.4%

Valuation

See full
Market cap$558.64M-10.7%
Enterprise value$609.98M-10.0%

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%—

Returns & leverage

See full
Return on equity-373.3%-1,281pp
Debt / equity2.8×+0.9×
Current ratio3.1×-0.5×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:03 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053883
(in thousands, except share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Research and development33,39741,37567,50281,937
General and administrative11,04213,11728,44726,401
Total operating expenses44,43954,49295,949108,338
Loss from operations(43,285)(53,377)(93,939)(105,769)
Other income:
Interest income7887431,8091,925
Accretion (amortization) of investments333530793869

Item 1. Financial Statements (unaudited)

FAQ

What is Prime Medicine's total operating expenses?
Prime Medicine (PRME) reported total operating expenses of $44.44M in Q2 2026.
How has Prime Medicine's total operating expenses changed year-over-year?
Prime Medicine's total operating expenses decreased by 18.4% year-over-year, from $54.49M to $44.44M.
What is the long-term trend for Prime Medicine's total operating expenses?
Over 3 years (2022 to 2025), Prime Medicine's total operating expenses has grown at a 22.3% compound annual growth rate (CAGR), from $116.54M to $212.98M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Prime Medicine's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude